← FDA DRUG APPROVALS

FDA BLA · BLA761312

LYMPHIR

denileukin diftitox-cxdl

Sponsor: CITIUS PHARMS

APPLICATION
BLA761312
TYPE
BLA
ORIGINAL APPROVAL
2024-08-07
LATEST ACTION
2024-08-07
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

LYMPHIRPrescription
DENILEUKIN DIFTITOX-CXDL 300MCG · INJECTABLE · INJECTION

Approval history

2024-08-07Type 5 - New Formulation or New Manufacturer · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →